跳转至内容
Merck
CN

D-011

Supelco

1,3-二硝基甘油 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

关于此项目

经验公式(希尔记法):
C3H6N2O7
CAS Number:
分子量:
182.09
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in acetonitrile

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

pharmaceutical (small molecule)

包装形式

single component solution

储存温度

−20°C

SMILES字符串

OC(CO[N+]([O-])=O)CO[N+]([O-])=O

InChI

1S/C3H6N2O7/c6-3(1-11-4(7)8)2-12-5(9)10/h3,6H,1-2H2

InChI key

ASIGVDLTBLZXNC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

1,3-二硝基甘油是药物血管扩张剂硝酸甘油的主要血浆代谢产物。该经认证的加标溶液®适用于药学研究或临床毒理学中基于色谱或质谱的应用。硝酸甘油用于治疗心脏病,例如心绞痛和慢性心力衰竭。

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

FlameExclamation mark

警示用语:

Danger

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

35.6 °F - closed cup

闪点(°C)

2 °C - closed cup

法规信息

危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

G S Marks et al.
Canadian journal of physiology and pharmacology, 70(6), 935-937 (1992-06-01)
Incubation of glyceryl trinitrate (GTN) with 5% (w/v) rat brain homogenate (RBH) resulted in biotransformation of the organic nitrate vasodilator drug to a mixture of glyceryl-1,2-dinitrate (1,2-GDN) and glyceryl-1,3-dinitrate (1,3-GDN). Heating of the RBH at 100 degrees C for 5
B Auclair et al.
Therapeutic drug monitoring, 20(6), 607-611 (1998-12-16)
The purpose of this study was to assess the ability of our previously constructed pharmacokinetic (PK) model to describe nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN) plasma concentrations after a single-dose application of a GTN transdermal matrix delivery system. GTN
R C Jewell et al.
Pharmaceutical research, 9(10), 1284-1289 (1992-10-01)
The FDA Cooperative Efficacy Study of transdermal nitroglycerin utilized a combination of marketed products over a wide dose range. Unfortunately, plasma nitroglycerin concentrations were not determined. The current study was conducted to assess plasma nitrate concentrations after transdermal doses of
M Gumbleton et al.
Journal of pharmacokinetics and biopharmaceutics, 21(5), 515-532 (1993-10-01)
The organic nitrate 1,3-glyceryl dinitrate (1,3-GDN) is one of the primary dinitrate metabolites of the antianginal agent nitroglycerin (GTN). Investigational New Drug Approval was sought to administer oral solution doses of 1,3-GDN to a small number (n = 3) of
T Fujii et al.
Biological & pharmaceutical bulletin, 19(8), 1093-1096 (1996-08-01)
Nitroglycerin (GTN) has been used as the drug of choice in the treatment of angina pectoris. It has been shown that some glutathione S-transferases (GSTs) catalyze the metabolic conversion from GTN to glyceryl dinitrates (GDNs). In this study, we examined

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持